Shots:
- Bayer has entered into an agreement to fully acquire Perfuse Therapeutics, incl. its asset PER-001, complementing Bayer’s pipeline & expertise in ophthalmology
- As per the deal, Bayer will acquire Perfuse for ~$2.45B, incl. $300M upfront payment & additional development, regulatory, & commercial milestone payments;
- PER-001 (intravitreal implant), a small molecule endothelin receptor antagonist, is being assessed in the P-II trials for the treatment of Glaucoma & Diabetic Retinopathy
Ref: Businesswire | Image: Perfuse Therapeutics | Press Release
Related News: Bayer Reports the P-III (FIND-CKD) Trial Data on Kerendia in Non-Diabetic Chronic Kidney Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
